Activation of caspases has been demonstrated to be involved in thrombocytopenia and prolonged storage of platelet concentrates. Platelets represent enucleate cells that comprise all elements of the mitochondrial apoptosis pathway. However, no apoptotic stimuli capable of activating the endogenous caspase cascade have been identified so far. Using tributyltin (TBT) we could identify a compound that is capable of activating caspase-9 and -3 in platelets. Recent studies implicate that TBT induces apoptosis via the mitochondrial signaling pathway that is characterized by the formation of a high-molecular-weight complex (apoptosome) containing the adapter protein Apaf-1 and active caspase-9. Interestingly, addition of TBT induced the activation of caspase-9 in an ultra-rapid kinetic within the first 2 min. In addition, size exclusion chromatography revealed that TBT-mediated processing of caspase-9 occurs in the absence of the apoptosome. Thus, these data implicate that TBT induces the activation of caspase-9 by a mechanism not involving the formation of the apoptosome.
Activation of caspases has been demonstrated to be involved in thrombocytopenia and prolonged storage of platelet concentrates. Platelets represent enucleate cells that comprise all elements of the mitochondrial apoptosis pathway. However, no apoptotic stimuli capable of activating the endogenous caspase cascade have been identified so far. Using tributyltin (TBT) we could identify a compound that is capable of activating caspase-9 and -3 in platelets. Recent studies implicate that TBT induces apoptosis via the mitochondrial signaling pathway that is characterized by the formation of a high-molecular-weight complex (apoptosome) containing the adapter protein Apaf-1 and active caspase-9. Interestingly, addition of TBT induced the activation of caspase-9 in an ultra-rapid kinetic within the first 2 min. In addition, size exclusion chromatography revealed that TBT-mediated processing of caspase-9 occurs in the absence of the apoptosome. Thus, these data implicate that TBT induces the activation of caspase-9 by a mechanism not involving the formation of the apoptosome. Oncogene (2003 Oncogene ( ) 22, 775-780. doi:10.1038 Keywords: Organotin; tributyltin; platelets; caspase-9; apoptosome; apoptosis The apoptotic program can be initiated via two major signaling pathways: the extrinsic death receptor pathway and the intrinsic mitochondrial pathway. Ligation of death receptors (such as CD95, TNR-R1, TRAMP or TRAIL-R1, -R2) with their respective ligand or agonistic antibodies recruits the adapter protein FADD to the active trimeric death receptor. FADD in turn recruits and activates the death protease caspase-8 (Schulze-Osthoff et al., 1998) . Caspase-8 like all other caspases is a cysteine protease and synthesized as a catalytically inactive proenzyme that is activated upon proteolytic cleavage. The mitochondrial death pathway is triggered by a number of apoptotic stimuli such as anticancer drugs, staurosporine, cycloheximide, UVand g-irradiation Bantel et al., 1999; Wesselborg et al., 1999; Belka et al., 2000; Engels et al., 2000) . This pathway is initiated at the mitochondrion and characterized by the mitochondrial release of cytochrome c. In the cytosol, cytochrome c together with dATP binds to the adapter protein Apaf-1, which subsequently oligomerizes and recruits procaspase-9 into a large heteromeric complex of B700 kDa, the socalled apoptosome. Activation of both pathways via initiator caspase-8 or -9 triggers an amplifying cascade of executioner caspases (as caspase-3, -6 and -7) that after cleavage of vital death substrates leads to the final demise of the cell .
Although apoptosis usually occurs in nucleated cells, it can also be induced in artificially enucleated cytoplasts upon stimulation with staurosporine or agonistic antibodies against CD95 (Schulze-Osthoff et al., 1994; Jacobsen et al., 1996) . Interestingly, mammalian organisms comprise two enucleated cellular minimal systems that contain part if not all components of the apoptotic machinery. One is represented by the mitochondriadeficient mature red blood cells, the other by the mitochondria-containing platelets. In this context, we and others could recently demonstrate that human red blood cells express caspase-3 and -8 but are devoid of mitochondrial regulators of apoptosis (Berg et al., 2001; Bratosin et al., 2001) . Using a plethora of apoptotic stimuli we failed to activate these caspases in vivo. Interestingly, stimulation with calcium ionophore induced apoptotic features including cell shrinkage, externalization of phosphatidyl serine, plasma membrane microvesiculation and cleavage of the cytoskeletal protein spectrin (Berg et al., 2001; Bratosin et al., 2001) . However, these features were not attributed to the activation of caspases but to the activation of the cysteine protease calpain. Similar results have been demonstrated for calcium ionophore in human platelets. Initial observations reported that calcium ionophore induces the degradation of caspase-3, thus claiming a calcium ionophore-mediated activation of caspases (Vanags et al., 1997; Shcherbina and Remold O'Donnell, 1999) . A detailed study by Wolf et al. (1999) could demonstrate that human platelets contain all elements of the mitochondrial death pathway, that is, Apaf-1, cytochrome c, caspase-9 and -3 and that this pathway could be activated in vitro via cytochrome c plus dATP. In addition, calcium ionophore induced apoptotic features such as microvesiculation, exposure of phosphatidyl serine and fragmentation of caspase-9, -3, and gelsolin. However, as in erythrocytes Wolf et al. (1999) could demonstrate that calcium ionophore did not activate caspases but calpain instead. Calpain proteolytically processed procaspase-3 and -9 in vitro and in whole platelets but at cleavage sites that rendered these caspases inactive. Nevertheless, recent reports suggest a crucial role for caspases in the death of platelets in thrombocytopenia and prolonged storage of platelet concentrates Piguet et al., 2002) . Caspase activation has also been detected during thrombopoiesis and the fragmentation of proplatelets from megakaryocytes, without a concomitant induction of cell death (De Botton et al., 2002) .
Since platelets would represent an ideal screening system for drugs that do not rely on DNA damage in order to induce apoptosis, we screened a plethora of different apoptotic stimuli as shown in Table 1 . Interestingly, most of the tested stimuli failed to activate any cleavage of caspases as tested by immunoblot analysis. Although platelets contain caspase-8 , the central initiator caspase of the death receptor pathway, agonistic antibodies could not instigate any caspase activity, which could be explained by a recent report demonstrating that platelets obviously lack the expression of CD95, TRAIL-R1 and -R2 (Plenchette et al., 2001 ). Interestingly, staurosporine, which has been demonstrated to activate the mitochondrial pathway differently from DNA-damaging agents (Stepczynska et al., 2001) and to induce apoptosis even in enucleated cytoplasts (Jacobsen et al., 1996) , could not mediate any caspase processing in human platelets. Neither did the anticancer drug etoposide that at 25 mm has been reported to induce directly the mitochondrial release of cytochrome c in vitro (Robertson et al., 2000) . The only stimulus capable of inducing caspase activity we could identify was tributyltin (TBT) ( Table 1) .
The triorganotin compound TBT is known for its immunotoxic effects such as depletion of cortical thymocytes, thymic atrophy, and immunosuppression in rats (Seinen et al., 1977; Vos et al., 1984; Snoeij et al., 1988) . In addition, in vitro studies showed that TBT activates caspases and induces apoptosis in rat thymocytes and human lymphoma cells (Vos et al., 1984 (Vos et al., , 1990 Aw et al., 1990; Chow et al., 1992; Raffray and Cohen, 1993; Stridh et al., 1998) . Recent studies demonstrated that TBT decreases the mitochondrial membrane potential (Dc) and triggers the release of cytochrome c (Stridh et al., 1998 (Stridh et al., , 1999b Nishikimi et al., 2001 ). In addition, TBT is known to inhibit the F 1 F 0 -ATPase (Cain et al., 1977) , anion channels (Powers and Beavis, 1991) and the adenine nucleotide translocator in the inner mitochondrial membrane (Harris et al., 1973; Nishikimi et al., 2001) . All these data implicate that the mitochondrial cytochrome c/Apaf-1-pathway might be the major target of TBT.
In order to investigate the kinetic of TBT-mediated caspase processing, we stimulated human platelets with 2 mm TBT for different amounts of time. Subsequently, cellular proteins were resolved on an SDS-polyacrylamide gel and the cleavage of the initiator caspase-8, -9 and of the executioner caspase-3 was monitored by immunoblotting. Surprisingly, TBT induced the proteolytic cleavage of procaspase-9 and -3 within the first 2 and 4 min, respectively (Figure 1a) . Thus, TBT mediated the processing of the 45 kDa procaspase-9 into the 37 kDa form generated by caspase-3 cleavage and the autoproteolytically processed p35 form of caspase-9. The 32 kDa proform of caspase-3 was processed into the typical p20 and p17 fragments. The proform of the two isoforms of caspase-8 slightly decreased upon TBT treatment, but we could not observe the typical p41/p43 intermediate fragments of caspase-8 as we did in staurosporine-stimulated Jurkat cells (Figure 1a ). Since calpain degrades procaspase-9 into fragments of B30-34 kDa and pro-caspase-3 into an B30 kDa fragment (Wolf et al., 1999) , calpain was most likely not involved in TBT-mediated processing of procaspase-9 and -3. Consistently, addition of the broad-spectrum caspase inhibitor zVAD-fmk prevented the proteolytic cleavage of procaspase-9 and -3. Since the analysis of caspase cleavage by immunoblotting does not provide any information about the enzymatic caspase activity, we determined the catalytic activity by cleavage of the fluorogenic caspase-3 substrate DEVD-AMC in a fluorimetric assay. As demonstrated in Figure 1b , stimulation with TBT induced caspase-3-like activity as early as 2 min after addition and reached almost fulllevel activity after 4 min. This rapid induction of caspase activity in platelets was surprising, since other known apoptotic stimuli that activate the mitochondrial death pathway such as anticancer drugs, staurosporine, mistletoe lectin I or g-irradiation usually require 1 h or even longer (Bantel et al., 1999; Wesselborg et al., 1999; Belka et al., 2000; Lauber et al., 2001; Stepczynska et al., 2001) . Even the direct addition of cytochrome c and dATP to cellular lysates of Jurkat cells consumes at least 10-20 min for the activation of procaspase-9 ). In addition, we investigated the loss of the mitochondrial membrane potential (DC m ) and the loss of viability upon TBT treatment by measuring the release of LDH and the loss of intracellular ATP. Thus, we could demonstrate that the rapid activation of caspases was paralleled by a rapid loss in DC m after 2 min ( Figure 1c ) and a subsequent decrease in platelet viability after 10 min (Figure 1d, e) .
The current model of activation of caspase-9 via the mitochondrial death pathway suggests that in the presence of cytochrome c and dATP Apaf-1 oligomerizes and recruits procaspase-9 into a large heteromeric complex of B700 kDa. In this so-called apoptosome, procaspase-9 is allosterically activated and is now able to recruit and activate procaspase-3. Therefore, we wanted to address the question whether TBT induces the activation of caspase-9 within the highmolecular-weight complex of the apoptosome. Accordingly, we stimulated platelets with 2 mm TBT for 10 min. Subsequently, mitochondria-depleted S100 extracts were prepared and cellular proteins and protein complexes were separated based on their molecular weight on a Superdex-200 gel filtration column. In order to activate the cytochrome c/Apaf-1 pathway 1 mm dATP and 10 mm cytochrome c were added directly to S100 extracts for 30 min before application to gel filtration. The processing of procaspase-9 in the respective fractions was detected by immunoblotting ( Figure 2a ) and the catalytic activity was monitored fluorometrically by the cleavage of DEVD-AMC (Figure 2b) . Treatment of cellular lysates with cytochrome c and dATP induced a shift from the monomeric uncleaved 45 kDa form of procaspase-9 observed in fractions 33-35 to the processed active forms of caspase-9 in the high-molecularweight complex in fraction 19. This high-molecularweight complex contained both, the caspase-3-cleaved p37 form of caspase-9 as well as the autoproteolytically processed p35 form of caspase-9. The p37 form of caspase-9 also appeared outside of the high-molecularweight complex in fractions 30-32. On the contrary, caspase-9 in TBT-treated platelets was also processed into p35 and p37, but these fragments occurred only in fractions 31-33 and could not be detected in the highmolecular-weight fractions (Figure 2a ). When the DEVDase activity of each fraction was monitored fluorometrically, there was also no caspase activity observable in the high-molecular-weight fractions in TBT-treated platelets, contrary to lysates treated with cytochrome c and dATP where the activity was evident in fractions 19 and 20. The activity of free caspases resided in the same fractions (fractions 32-36) in both TBT-treated platelets and cytochrome c plus dATPtreated lysates (Figure 2b) .
Taken together, our data of the rapid kinetics of TBTmediated caspase-9 cleavage and the observation that caspase-9 is not part of a high-molecular-weight complex implicates that caspase-9 is most likely processed and activated outside of the apoptosome. Our data in human platelets are in line with the recent findings in human eosinophils and neutrophils, where a rapid activation of caspase-3 by TBT was suggested to occur independent of mitochondrial alterations (Nopp et al., 2002) . Using exogenous cytochrome c and dATP, we could confirm previous studies demonstrating that apoptosome formation could be induced in human platelets that contain all elements of the mitochondrial apoptosis pathway including Apaf-1, cytochrome c, caspase-9 and caspase-3 (Wolf et al., 1999) . The lack of apoptosome formation might explain why the overexpression of the antiapoptotic proteins Bcl-2 and Bclx L protected only moderately from TBT-induced apoptosis in Jurkat T cells (Stridh et al., 1999a) . Since antiapoptotic members of the Bcl-2 family inhibit the mitochondrial release of cytochrome c, it is conceivable that the TBT-induced cytosolic relocation of cytochrome c is not required for the activation of caspase-9. Moreover, since human platelets lack the surface expression of death receptors (Plenchette et al., 2001 ), a role of death receptors in TBT-induced activation of procaspase-9 can further be excluded. Consistently, we could not observe any processing of procaspase-8 upon treatment with TBT. Another crucial element for the activation of caspases via TBT is the intracellular calcium concentration, which is increased upon TBT treatment. Chelation of intra-or extracellular calcium or the use of calcium-free medium did not prevent the loss of the mitochondrial membrane potential nor the release of cytochrome c but potently decreased the DEVDase activity in Jurkat cells (Stridh et al., 1999b) . In this context, the calcium-activated cysteine protease calpain might be considered as a potential candidate. Calpain has been demonstrated to cleave procaspase-3 and -9. But since calpain-mediated processing results in a different cleavage pattern that renders these caspases inactive (Wolf et al., 1999) , calpain is most likely not involved in TBT-mediated caspase activation. In this context, other signaling pathways as the lysosomal cathepsin release (Leist and Ja¨a¨ttela¨, 2001) or induction of stress to the endoplasmic reticulum (ER) by, for example, thapsigargin might be considered (Nakagawa et al., 2000; Rao et al., 2002) . However, since addition of cathepsin inhibitors only slightly reduced TBT-induced Figure 1 Kinetic analysis of TBT-mediated processing of caspases and catalytic activity in human platelets. Freshly isolated platelets from normal healthy donors were prepared as described by Shcherbina and Remold O'Donnell (1999) . (a) A total of 5 Â 10 7 platelets were pretreated with or without 100 mm zVAD-fmk for 45 min and subsequently stimulated with 2 mm TBT for the indicated duration of time. Cellular proteins were resolved by SDS-PAGE and proteolytic processing of procaspase-9 and -3 was detected by immunoblotting as described by Lauber et al. (2001) . DEVDase activity and thapsigargin had no effect on the activation of caspases in human platelets (data not shown), we conclude that cathepsins or ER stress are not central elements in TBT-induced caspase activation. Another potential signaling mechanism might be the Akt/PKB pathway, since Akt has been described to phosphorylate caspase-9 and to interfere with caspase-9 activation (Cardone et al., 1998) or other apoptosomeindependent pathways (Marsden et al., 2002) . Thus, future studies have to address the question how TBT activates procaspase-9 in the absence of apoptosome formation. In addition, using the apoptotic stimulus TBT, we could demonstrate that the nuclei-deficient platelets might represent an ideal screening system for Figure 2 TBT-induced processing of caspase-9 apparently occurs outside of the high-molecular-weight complex of the apoptosome. Freshly prepared platelets were left untreated or stimulated for 10 min with 2 mm TBT. Subsequently, cytosolic mitochondria-free S100 extracts were prepared as previously described . Untreated lysates were treated with 10 mm purified cytochrome c and 1 mm dATP for 30 min. S100 extracts (3.5 mg) of untreated or TBT-treated whole platelets or cytosolic extracts stimulated with cytochrome c plus dATP were fractionated by size exclusion chromatography on a Superdex-200 gel filtration column as described by Lauber et al. (2001) . (a) Fractions of 500 ml were collected and aliquots of 100 ml were subjected to SDS-PAGE followed by immunoblot analysis against caspase-9. Filled arrowheads show the uncleaved and open arrowheads the cleaved form of caspase-9. An asterisk indicates a nonspecific band in caspase-9 Western blots. The fraction number applied to immunoblot analysis is shown at the top. Elution positions of molecular weight standards are marked with arrows at the top. The positions of the apoptosome and the free caspases are indicated with brackets at the bottom. (b) An aliquot of 100 ml of the chromatographic fractions prepared in (a) was assayed fluorimetrically for DEVDase activity as described in Figure 1b . Caspase activity is given in arbitrary fluorescent units per minute. DEVDase activity in S100 lysates of untreated platelets are shown with dashed line and open circles, S100 lysates of TBTtreated platelets are indicated with a continuous line and closed circles and S100 lysates treated with cytochrome c plus dATP are shown with continuous line and closed triangles. Mean values7s.d. from triplicate experiments are shown the indicated time points. (b) Subsequently, cell lysates were prepared, incubated with 50 mm of the fluorogenic substrate Ac-DEVD-AMC (N-acetyl-Asp-Glu-Val-Asp-aminomethyl-coumarin) and measured in a spectrofluorometer as previously described . Caspase activity was determined as the slope of the resulting linear regressions and expressed in arbitrary fluorescence units/min. Mean values7s.d. from triplicate experiments are shown. (c) The loss of the mitochondrial membrane potential (DC m ) was detected using the fluorescent DC m indicator tetramethylrhodamine ethyl ester (TMRE) and subsequent analysis by flow cytometry as described by Belka et al. (2000) . Platelet viability was measured by (d) the release of LDH (LDH-Cytotoxicity Assay Kit, BioVision, CA, USA) or (e) the loss of intracellular ATP (ApoSensorTM Cell Viability Kit, BioVision, CA, USA) and subsequent analysis in a luminometer and ELISA reader, respectively apoptotic agents that activate the endogenous caspase cascade in the absence of gene expression or DNA damage.
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